Grupo Cooperativo De Estudio Y Tratamiento De Las Leucemias Agudas Y Mielodisplasias

The sponsor’s clinical research is centered on acute myeloid leukemia cases with persistent or recurrent measurable residual disease after frontline treatment, with attention to patients whose disease remains detectable despite prior intensive therapy.

• MRD persistence
• MRD reappearance
• Frontline chemotherapy

Its research focus includes disease monitoring in AML during post-treatment follow-up, particularly where residual disease status may influence subsequent therapeutic decisions.